Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?

Q2 Medicine Interventional Medicine and Applied Science Pub Date : 2019-11-11 eCollection Date: 2020-09-01 DOI:10.1556/1646.10.2018.32

Nafiye Yilmaz, Necati Hancerliogullari, Mustafa Kara, Yaprak Engin-Ustun

{"title":"Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?","authors":"Nafiye Yilmaz, Necati Hancerliogullari, Mustafa Kara, Yaprak Engin-Ustun","doi":"10.1556/1646.10.2018.32","DOIUrl":null,"url":null,"abstract":"Objectives: Gonadotropin-releasing hormone agonist (GnRHa) could influence the levels of sex hormones and thyroid hormones. The aim of this study was to investigate the effect of GnRHa on thyroid function.Materials and methods: The data of the patients were collected from the registrations of July 2014-October 2014. A total of 41 women who underwent one-time IVF cyclus were evaluated in this cross-sectional study. The patients were categorized into two groups according to the serum T3, T4, and TSH levels before and 2 weeks' after the administration of GnRHa.Results: Mean basal TSH and mean TSH levels on hCG day were 1.98 ± 0.77 and 1.75 ± 0.70, respectively. The difference between the two groups was statistically significant (p < 0.05). GnRHa did not lead to statistically significant difference on serum-free T3 and T4 levels.Conclusions: In conclusion, our results demonstrate that GnRHa led to a decrease on serum TSH level. Serum-free T3 and T4 levels were remained unchanged and this might be due to early measurement of the hormone levels (just 2 weeks later from GnRHa administration).","PeriodicalId":45181,"journal":{"name":"Interventional Medicine and Applied Science","volume":"11 3","pages":"136-138"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/68/imas-11-136.PMC9467336.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional Medicine and Applied Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1556/1646.10.2018.32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Gonadotropin-releasing hormone agonist (GnRHa) could influence the levels of sex hormones and thyroid hormones. The aim of this study was to investigate the effect of GnRHa on thyroid function.

Materials and methods: The data of the patients were collected from the registrations of July 2014-October 2014. A total of 41 women who underwent one-time IVF cyclus were evaluated in this cross-sectional study. The patients were categorized into two groups according to the serum T₃, T₄, and TSH levels before and 2 weeks' after the administration of GnRHa.

Results: Mean basal TSH and mean TSH levels on hCG day were 1.98 ± 0.77 and 1.75 ± 0.70, respectively. The difference between the two groups was statistically significant (p < 0.05). GnRHa did not lead to statistically significant difference on serum-free T₃ and T₄ levels.

Conclusions: In conclusion, our results demonstrate that GnRHa led to a decrease on serum TSH level. Serum-free T₃ and T₄ levels were remained unchanged and this might be due to early measurement of the hormone levels (just 2 weeks later from GnRHa administration).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

促性腺激素释放激素激动剂的使用真的会导致甲状腺功能障碍吗?

目的:促性腺激素释放激素激动剂(GnRHa)对性激素和甲状腺激素水平的影响。本研究旨在探讨GnRHa对甲状腺功能的影响。材料与方法:患者资料收集于2014年7月- 2014年10月登记。在这项横断面研究中，共有41名接受过一次性试管婴儿周期的妇女进行了评估。根据给药前和给药后2周血清T3、T4、TSH水平将患者分为两组。结果:hCG日平均基础TSH和平均TSH水平分别为1.98±0.77和1.75±0.70。两组患者t3、T4水平差异有统计学意义。结论:总之，我们的研究结果表明，GnRHa导致血清TSH水平降低。血清游离T3和T4水平保持不变，这可能是由于早期测量激素水平(仅在GnRHa给药后2周)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊